


ACCP Virtual Journal Club Webinars!

Edoxaban Exposure in Patients with Atrial Fibrillation and Estimated Creatinine Clearance Exceeding 100 mL/min

2024 ACCP Virtual Journal Club Webinar

Live Session: Wednesday, March 20th, 2024, from 2:00 to 3:00 PM ET

On Demand: March 20th, 2024 to March 20th, 2027



Why is this webinar important to you?

There is a lack of clear understanding of high creatinine clearance on pharmacokinetic/pharmacodynamic (PK/PD) outcomes. Edoxaban 60 mg is approved for stroke prevention in patients with atrial fibrillation (AF) not fulfilling any dose-reduction criteria. As edoxaban is partially renally cleared ($\approx 50\%$), it was postulated that edoxaban exposure may be lower in patients with high creatinine clearance ($\text{CrCL} > 100 \text{ mL/min}$); thus, efficacy could hypothetically be lower in this subpopulation. In this webinar, the author will discuss a prospective, randomized, double-blinded study comparing the pharmacokinetics, pharmacodynamics, efficacy and safety outcomes of edoxaban 60 mg once daily versus edoxaban 75 mg once daily in patients with CrCL exceeding 100 mL/min. The presentation will also illustrate the utility of population PK modeling to account for variability and estimate steady-state PK values based on the sparse PK concentrations collected in the study.



ACPE Accreditation Statement

The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

UAN: 0238-0000-24-003-L01-P & 0238-0000-24-003-H01-P

Contact Hours: 1.0

Activity Type: Knowledge-based

Format: Live and Home-study

Target Audience: 'P'



ACCME Accreditation Statement

The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

ACCME Designation Statement

The Accreditation Council for Continuing Medical Education designates this journal CE activity for 1 *AMA PRA Category 1™* credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Target Audience

Interprofessional team of Physicians, Pharmacists, PhDs, and other health care professionals.

Learning Objectives

After completing this activity, the learner will be able to:

1. Describe the impact of high creatinine clearance on edoxaban PK and PD and the potential clinical implications;
2. Recognize the utility of population PK modeling in analyzing sparse PK concentrations collected from clinical studies;
3. Describe the key elements of a prospective, randomized, placebo-controlled clinical trial.

Faculty:

Author/Faculty: Ophelia Yin, PhD - Vice President, Head of Clinical Pharmacology, iTeos Therapeutics Inc

Moderator/Planner: Stefanie Drescher, PhD, Manager, Clinical Pharmacology, Pfizer Inc

All of the relevant financial relationships for these individuals have been mitigated.

Schedule & Fees

ACCP webinar programs occur several times per year. Registration for the webinars is required but free of charge to all learners.

Helpful Tips

For best audio and visual quality, we recommend viewing the webinar in the Chrome browser. If you do not have Chrome, you may download it [here](#).

Test your browser compatibility before the webinar by clicking [here](#).

Download the article and slide handouts and access the webinar [here](#).